Of the 1,505 patients in the LIBERTY ASTHMA QUEST study, 282 had fungal sensitization at baseline; of those, 155 were on high-dose ICS (placebo, 63; dupilumab, 92) and 127 were on medium-dose ICS ...

LOUISVILLE, Ky. — Patients with asthma faced high risks for exacerbations despite their maintenance medication or disease severity, reported researchers at the American College of Allergy ...

When compared to high-dose ICS treatment paired with a placebo, the monoclonal antibody with medium-dose ICS treatment reduced severe asthma exacerbations by 70% (0.273 vs 0.899 per year, P<0.0001 ...

Maintenance of asthma was defined as no asthma exacerbations since the previous visit, no increase in Asthma Control Questionnaire (ACQ-5), and no significant increase in ICS-formoterol reliever ...

Stepping down to as-needed ICS/FABA maintained asthma stability while significantly reducing steroid exposure in individuals ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

TUESDAY, Oct. 29, 2024 (HealthDay News) -- For patients with asthma, inhaled corticosteroids (ICS) combined with short-acting β agonists (SABA) and ICS combined with the long-acting β agonist ...

Compared with albuterol rescue, PT027 at the 180mcg albuterol/160mcg budesonide dose reduced the risk of a severe exacerbation by 27% (p<0.001) in adults and adolescents. 1,2 In the trial ...

Conversely, ICS use is controversial in COPD and only the medium doses of ICS in fixed combinations ICS + LABA inhalers are FDA-approved to control symptoms and reduce acute exacerbations – that ...

Albuterol/budesonide, previously known as PT027, is a short-acting beta2-agonist (SABA) and inhaled corticosteroid (ICS) asthma rescue therapy approved under the brand name Airsupra ®.